Advancements in Obesity Treatments: The Role of Oral Semaglutide

Medical treatments for obesity are witnessing significant advancements thanks to advanced research and clinical studies. One such development is the use of oral semaglutide, which has proven effective in weight management. In this article, we will review the results of the OASIS 4 study published in The New England Journal of Medicine, which confirmed the benefits of this new treatment.

Results of the OASIS 4 Clinical Study

The OASIS 4 study was conducted over 64 weeks and involved 307 adults suffering from obesity or overweight, with a weight-related health condition. The effectiveness of oral semaglutide at a dose of 25 mg was compared to a placebo, alongside lifestyle changes.

The results showed that participants who adhered to the treatment lost an average of 16.6% of their body weight, compared to only 2.7% in the placebo group. Notably, more than a third of the participants (34.4%) lost at least 20% of their weight, compared to 2.9% in the control group.

Improvements in Physical and Cardiovascular Health

In addition to weight loss, the study showed improvements in daily physical body functions, such as bending, walking, and standing, as well as improvements in cardiovascular risk indicators. These results align with previous data related to injectable Wegovy.

The study also confirmed improved physical activity levels among participants, enhancing the overall health benefits of oral semaglutide treatment.

Side Effects and Tolerance

The study indicated that the side effects of oral semaglutide were mostly mild to moderate and temporary. The most common symptoms were nausea and vomiting, experienced by 46.6% and 30.9% of participants, respectively.

However, serious adverse events were less common among participants who received the drug compared to the placebo group, confirming the long-term safety of the treatment.

Expert Guidance and Future Expectations

Martin Holst Lange, Chief Scientific Officer at Novo Nordisk, stated that the data on oral semaglutide at a dose of 25 mg shows strong efficacy as an oral weight management drug. He anticipated that if approved by the U.S. Food and Drug Administration, there would be ample supply to meet the expected demand in the United States.

Sean Wharton, the study director, also noted that oral semaglutide represents a significant step forward in obesity treatment, expanding therapeutic options for individuals who prefer oral medications.

Conclusion

The OASIS 4 study represents a significant achievement in the field of obesity treatment, demonstrating the effectiveness of oral semaglutide in achieving sustainable weight loss and improving overall health. Thanks to this development, individuals suffering from obesity or overweight may have a new treatment option that meets their individual needs and opens new horizons in long-term weight management.